Is Foam Sclerotherapy Dangerous? Risks and Side Effects

Foam sclerotherapy is not considered dangerous for most people, but it carries a real set of risks that range from mild cosmetic nuisances to rare but serious events like deep vein thrombosis and transient neurological symptoms. The procedure, which involves injecting a foam sclerosant into problematic veins to collapse them, is one of the most widely used treatments for varicose and reticular veins. Understanding where the risks actually lie, how common they are, and what makes some patients more vulnerable gives you a much clearer picture than a simple “safe or not” answer can.

The Most Common Side Effects

The side effects most people experience after foam sclerotherapy are annoying rather than alarming. Pain at the injection site, bruising, and temporary skin darkening (hyperpigmentation) top the list. In a retrospective review of over 300 foam sclerotherapy patients, the average severity ratings for adverse events were minimal to mild across all categories, including hyperpigmentation, ulceration, pain, and new vessel formation, with no serious adverse events recorded.¹ A controlled trial comparing foam and liquid sclerotherapy found that pain and hyperpigmentation were higher in the foam group at both 15 and 30 days after treatment.²

Superficial thrombophlebitis, an inflammation of veins near the skin surface, is another frequently reported complication. It usually shows up as a tender, firm cord along the treated vein and resolves on its own. In a study of ultrasound-guided foam sclerotherapy for recurrent varicose veins, superficial thrombophlebitis occurred in about 8% of injection sessions, with legs that had proximal reflux from incomplete prior surgery experiencing it far more often.³ Post-procedure compression stockings and early walking help reduce this complication.⁴

Deep Vein Thrombosis and Pulmonary Embolism

The blood clot risk is what worries most people, and the answer here depends a lot on what is being treated and how much foam is used. In a study of 1,000 legs treated with ultrasound-guided foam sclerotherapy, deep vein thrombosis (DVT) was detected in about 1.5% of cases. Most of these clots were small and confined to the area near the treated vein. Only two treatments out of 1,166 resulted in a DVT that caused symptoms, and regression analysis showed the risk jumped when 10 mL or more of foam was injected, with odds roughly four and a half times higher.⁵

A single-institution case series looking specifically at tibial vein thrombosis after foam sclerotherapy found it in 9% of patients who had follow-up imaging. That sounds high, but context matters: all of these clots were on the same side as the treatment, over half resolved completely within about five weeks, none of the patients developed pulmonary embolism, and symptoms resolved in the vast majority regardless of whether they were managed with blood thinners, antiplatelet drugs, or just observation.⁶ Pulmonary embolism itself is very rare. One review described it occurring in just one case out of 1,356 patients, placing serious complication rates somewhere in the range of 0 to about 6%.⁷

The volume of foam injected is the single most consistent risk factor for thrombotic complications across the literature. Guidelines recommend keeping foam volumes below 4 to 10 mL when treating saphenous trunks or veins with open pathways to deeper circulation, though larger volumes can be used more safely for smaller tributaries once the main trunks have already been ablated.⁸

Neurological Symptoms and Visual Disturbances

Transient neurological symptoms after foam sclerotherapy get a lot of attention, partly because they can be genuinely frightening even when they pass quickly. These episodes typically look like a migraine aura: flickering or shimmering visual disturbances, sometimes accompanied by tingling, numbness, or brief difficulty finding words. A systematic review spanning over 22,000 foam sclerotherapy sessions found transient neurological symptoms in about 0.5% of sessions. By comparison, liquid sclerotherapy sessions had an incidence closer to 0.09%.⁹

That roughly five-fold difference in neurological event rates between foam and liquid is thought to relate to the gas bubbles in foam. When tiny bubbles cross into the arterial circulation, particularly through a patent foramen ovale (a small hole between the heart’s upper chambers that about a quarter of adults have), they can reach the brain and trigger migraine-like symptoms. A separate dataset of over 10,000 foam sclerotherapy procedures reported neurological events in about 0.9% of cases, including visual and speech disturbances and 29 cases of migraine.¹⁰

A detailed clinical assessment of 20 patients who developed visual disturbances after foam sclerotherapy found that the episodes had characteristics of migraine aura in every case. Half of these patients also had headache, five experienced tingling, and one had brief speech difficulty.¹¹ These episodes are genuinely unsettling in the moment but almost always self-limiting, typically resolving within 30 to 60 minutes. Stroke is an extremely rare outcome reported only in isolated cases across large surveys, not something that shows up at measurable rates in clinical series.

Why the Gas in the Foam Matters

Traditional foam sclerotherapy mixes the sclerosant drug with room air. But air is mostly nitrogen, and nitrogen dissolves slowly in blood. Carbon dioxide and oxygen, by contrast, dissolve rapidly. This difference turns out to matter for side effects. A trial comparing CO₂-based foam with air-based foam found that switching to CO₂ cut the proportion of patients reporting any side effects from 39% down to 11%. Chest tightness, dry cough, and dizziness all dropped significantly with CO₂-based foam.¹²

A separate study of 470 patients comparing air-based and physiological-gas foam found that systemic side effects were rare with either gas. Only one patient in the entire series experienced transient blurred vision, and none reported chest tightness, dry cough, or dizziness.¹³ Many clinics have moved toward physiological gas mixtures specifically because of this side-effect profile, though availability varies by region.

Cosmetic Complications That Linger

For people getting foam sclerotherapy for cosmetic reasons, the irony of developing new visible veins after treatment is a genuine frustration. Telangiectatic matting refers to a web of fine new blood vessels that appears in or near the treated area. Estimates of how often it happens range from about 15% to 24% of patients.¹⁴¹⁵ The good news is that matting usually fades on its own within three to twelve months. In some cases, though, it persists and may need additional treatment with laser or repeat sclerotherapy.

Hyperpigmentation, the brownish discoloration that follows the path of a treated vein, is the other common cosmetic complaint. It results from hemosiderin deposits left behind as trapped blood breaks down. A randomized trial comparing foam sclerotherapy with a cryo-laser technique for reticular veins found no significant difference in pigmentation rates between the two approaches, suggesting this side effect is somewhat inherent to sclerotherapy in general rather than unique to foam.¹⁶ In most patients, hyperpigmentation fades over months, but it can occasionally take a year or longer to fully resolve, and in rare instances it becomes permanent.

Inadvertent Arterial Injection

This is the complication practitioners worry about the most, even though it is uncommon. If sclerosant is accidentally injected into an artery instead of a vein, it can damage tissue downstream by destroying blood supply. One case report described a patient developing skin necrosis after injection of a small amount of liquid sclerosant into an artery during treatment of spider veins.¹⁷ More severe cases have resulted in tissue loss or, in rare circumstances, amputation of digits or limbs. A report of three cases managed over a decade highlighted that both foam and liquid sclerosants can cause this when accidentally directed into an artery.¹⁸

Guidelines exist specifically for managing this complication, recognizing that immediate treatment can make a substantial difference in outcomes.¹⁹ Ultrasound guidance during injection reduces this risk considerably because it lets the practitioner see exactly where the needle tip is in real time. This is one reason that foam sclerotherapy for larger veins is almost always done under ultrasound, while injection of tiny spider veins by direct vision carries a small but nonzero risk of hitting a small artery running alongside or beneath the target vein.

Anaphylaxis and Severe Allergic Reactions

True anaphylaxis to sclerosant agents is exceptionally rare, but it has been documented. A case report described a patient who suffered cardiac arrest after microsclerotherapy with a very low concentration and volume of polidocanol. The patient had a swollen face and red rash on admission, along with a family history of allergy, pointing to anaphylaxis as the most likely cause.²⁰ Events like this are the reason known allergy to the sclerosant agent is an absolute contraindication, and why practitioners should have resuscitation equipment accessible during treatments.

Who Should Not Have Foam Sclerotherapy

Not everyone is a good candidate. The contraindications fall into two buckets: absolute (you should not have it, period) and relative (you could potentially have it, but the risk-benefit calculation shifts).

Absolute contraindications include:

• Known allergy: hypersensitivity to the sclerosant agent.
• Acute blood clots: active deep vein thrombosis or pulmonary embolism.
• Acute systemic illness: active infection or serious acute illness.
• Severe limb ischemia: chronic limb-threatening lack of blood flow.
• Previous severe reaction: a prior serious neurological or cardiac adverse event from sclerotherapy.

Relative contraindications, where extra caution and discussion are warranted, include pregnancy and breastfeeding, chronic systemic disease including severe obesity, elevated risk of venous thromboembolism, a known patent foramen ovale (because of the neurological symptom risk), and use of estrogen-containing medications.⁸ If you have a personal or family history of blood clots, that does not automatically disqualify you, but your practitioner should factor it into the treatment plan, potentially adjusting foam volume or adding precautionary anticoagulation.

How Foam Compares to Liquid Sclerotherapy on Safety

Foam is more effective than liquid for larger veins because it displaces blood and maintains contact with the vein wall longer. A multicenter randomized trial comparing foam and liquid polidocanol for treating the great saphenous vein confirmed that foam produced greater venous spasm and a longer sclerotic reaction, both signs of more effective treatment. The study found no difference in bruising, inflammatory reactions, or other side effects between the two forms.²¹

Where foam does appear to carry more risk is in neurological side effects. As noted earlier, the systematic review data shows about five times more transient neurological events per session with foam than with liquid. This is a consistent finding across studies and ties back to the gas bubble mechanism. For small spider veins and telangiectasias, liquid sclerotherapy often works just as well and avoids the foam-specific risk profile entirely. For trunk veins and larger varicosities, the greater effectiveness of foam generally justifies its slightly higher side-effect burden, though this is a conversation worth having with your treating physician.

There is also a difference in how the two sclerosant drugs commonly used, polidocanol and sodium tetradecyl sulphate (STS), interact with vein tissue. In-vitro testing found that STS caused deeper injury to the vein wall than polidocanol at equivalent time points, penetrating into the muscle layer of the vessel, while polidocanol damage remained confined to the inner lining.²² In practice, both agents are widely used and considered safe, but the choice between them can influence the side-effect profile depending on the veins being treated.

Foam Sclerotherapy Versus Thermal Ablation

If you are weighing foam sclerotherapy against radiofrequency or laser ablation, safety enters the decision alongside cost and convenience. A randomized trial comparing foam sclerotherapy with radiofrequency ablation for great saphenous vein incompetence found that both procedures allowed patients to return to daily activities within one day, and both produced similar reductions in pain scores.²³ Thermal ablation avoids the gas bubble issue entirely, so it does not carry the same neurological side-effect risk. On the other hand, it requires tumescent anesthesia (injections of dilute local anesthetic around the vein), which adds time and its own set of minor discomforts. In clinical trials comparing foam to thermal ablation for staged treatment, compression stockings were used for about a week after each approach, suggesting similar post-procedure care requirements.²⁴

Foam sclerotherapy tends to be less expensive than thermal ablation and can be performed in a standard office setting without an operating room. This accessibility is one reason it remains popular worldwide, particularly for patients who need repeat treatments or who have recurrent varicose veins after previous surgery. The trade-off is a somewhat higher recurrence rate with foam compared to thermal methods, meaning you may need additional sessions down the line. From a pure safety standpoint, neither approach is clearly riskier than the other for the average patient, though the specific risk profiles differ.

When Veins Come Back After Surgery

Foam sclerotherapy has carved out a particular niche in treating varicose veins that recur after surgical stripping or ligation. Reoperation carries higher complication rates because of scar tissue from the first surgery, so a needle-based approach is appealing. The study of ultrasound-guided foam sclerotherapy for recurrent varicose veins found no deep vein thrombosis or systemic complications, though superficial thrombophlebitis was considerably more common in legs that had proximal reflux feeding from an incompletely ligated junction or a pelvic vein, occurring in a third of those cases compared to just 3% in legs without that pattern.³ This means the anatomy of your recurrence influences your individual risk more than the procedure itself does. A thorough duplex ultrasound assessment before treatment lets practitioners identify high-risk patterns and adjust their approach accordingly, whether that means smaller foam volumes, staged treatments, or combining foam with thermal ablation to first close off the main reflux source.